Literature DB >> 11342647

Herpes simplex inhibits the capacity of lymphoblastoid B cell lines to stimulate CD4+ T cells.

S Barcy1, L Corey.   

Abstract

HSV establish a lifelong persistent infection in their host even among immunocompetent persons. The viruses use a variety of immune evasion strategies, presumably to assist persistent replication in the human host. We have observed that infection of human B lymphoblastoid cells (B-LCL) by HSV resulted in a strong inhibition of their ability to induce CD4(+) T cell clone proliferation and cytokine secretion. This inhibitory effect occurs in a variety of both HSV- and HIV-specific clones from three different patients. The inhibition is observed when the Ag is provided either as a soluble protein or as a synthetic peptide and is not associated with detectable down-modulation of the MHC class II molecules or costimulatory molecules. Expression of the HSV-1 unique sequence 1 gene (US1) is necessary and sufficient to induce this inhibition of APC function. US1 gene expression also made B-LCL less susceptible to CD4(+) T cell-mediated lysis. These data indicate a novel immune evasion strategy by HSV-1 in which Ag-processing cells that become infected by HSV-1 are inhibited in their ability to induce subsequent CD4(+) T cell activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342647     DOI: 10.4049/jimmunol.166.10.6242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Sequence variation in the herpes simplex virus U(S)1 ocular virulence determinant.

Authors:  Aaron W Kolb; Timothy R Schmidt; David W Dyer; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-28       Impact factor: 4.799

2.  Longitudinal analysis of herpes simplex virus-specific CD4+ cell clonotypes in infected tissues and blood.

Authors:  Serge Barcy; Meei-Li Huang; Lawrence Corey; David M Koelle
Journal:  J Infect Dis       Date:  2005-05-12       Impact factor: 5.226

3.  The Us3 Protein of Herpes Simplex Virus 1 Inhibits T Cell Signaling by Confining Linker for Activation of T Cells (LAT) Activation via TRAF6 Protein.

Authors:  Yin Yang; Songfang Wu; Yu Wang; Shuang Pan; Bei Lan; Yaohui Liu; Liming Zhang; Qianli Leng; Da Chen; Cuizhu Zhang; Bin He; Youjia Cao
Journal:  J Biol Chem       Date:  2015-04-23       Impact factor: 5.157

Review 4.  Induction and function of virus-specific CD4+ T cell responses.

Authors:  Jason K Whitmire
Journal:  Virology       Date:  2011-01-14       Impact factor: 3.616

5.  Human CD4+ T cell response to human herpesvirus 6.

Authors:  Maria-D Nastke; Aniuska Becerra; Liusong Yin; Omar Dominguez-Amorocho; Laura Gibson; Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  J Virol       Date:  2012-02-22       Impact factor: 5.103

6.  B7 costimulation molecules expressed from the herpes simplex virus 2 genome rescue immune induction in B7-deficient mice.

Authors:  Lydia G Thebeau; Sri P Vagvala; Yee M Wong; Lynda A Morrison
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

7.  Cell surface major histocompatibility complex class II proteins are regulated by the products of the gamma(1)34.5 and U(L)41 genes of herpes simplex virus 1.

Authors:  Joanne Trgovcich; David Johnson; Bernard Roizman
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 8.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

Review 9.  Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway.

Authors:  Jianmin Zuo; Martin Rowe
Journal:  Viruses       Date:  2012-08-22       Impact factor: 5.048

10.  HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts.

Authors:  Jason D Barbour; Mariana M Sauer; Elizabeth R Sharp; Keith E Garrison; Brian R Long; Helena Tomiyama; Katia C Bassichetto; Solange M Oliveira; Maria C Abbate; Douglas F Nixon; Esper G Kallas
Journal:  PLoS One       Date:  2007-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.